ERYTECH Pharma S.A. Logo

ERYTECH Pharma S.A.

Developing phage therapies to combat antibiotic-resistant bacterial infections.

ERYP | PA

Overview

Corporate Details

ISIN(s):
FR0010417360 (+2 more)
LEI:
969500U8ZZCODU8A9374
Country:
France
Address:
60 AVENUE ROCKEFELLER, 69008 LYON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PHAXIAM Therapeutics SA, formerly ERYTECH Pharma S.A., is a biopharmaceutical company developing antibacterial treatments based on bacteriophage (phage) therapy. The company focuses on combating bacterial infections, particularly those resistant to antibiotics. Its therapeutic approach utilizes phages—viruses that specifically target and destroy bacteria—to offer a highly targeted treatment for microbial infections, including multi-drug resistant strains. This represents a strategic shift from the company's former focus under the ERYTECH name, which centered on developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-18 07:00
Delisting Announcement
Informations privilégiées / Autres communiqués
French 168.4 KB
2025-06-18 07:00
Delisting Announcement
Inside Information / Other news releases
English 169.6 KB
2025-06-12 18:00
Delisting Announcement
Informations privilégiées / Autres communiqués
French 173.5 KB
2025-06-12 18:00
Delisting Announcement
Inside Information / Other news releases
English 180.8 KB
2025-06-05 07:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 116.9 KB
2025-06-05 07:00
Delisting Announcement
Inside Information / Other news releases
English 121.1 KB
2025-05-22 18:00
Delisting Announcement
Inside Information / Other news releases
English 118.8 KB
2025-05-22 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 116.6 KB
2025-05-05 07:00
Legal Proceedings Report
Inside Information / Other news releases
English 118.8 KB
2025-05-05 07:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 118.4 KB
2025-04-24 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 155.0 KB
2025-04-24 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 125.4 KB
2025-03-14 17:45
Legal Proceedings Report
Inside Information / Other news releases
English 168.3 KB
2025-03-14 17:45
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 172.5 KB
2025-03-06 17:56
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 159.2 KB

Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-23 N/A Other Other 3,697,533 2,255,495.13 EUR
2023-06-23 N/A Other Other 71,839 43,821.79 EUR
2023-06-23 N/A Other Other 54,862 33,465.82 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.